Advisory Committee

Derek Adams | Chief Technology and Manufacturing Officer | Bluebird Bio

Derek Adams

Chief Executive Officer
Stellular Bio

Derek is the CEO of Stellular Bio (Formerly Platelet Bio)
Previously, Derek has served as chief technology and manufacturing officer at bluebird bio. SVP of CMC at Evelo Bioscience, and VP Technical & Strategic Product Development at Alexion Pharmaceuticals.

Prior to joining bluebird, Derek was the senior vice president of CMC at Evelo Biosciences. At Evelo, Derek established the initial process development function and supply chain for clinical studies and drove strategy for product development. Prior to his time at Evelo, he served as vice president of technical and Strategic Product Development at Alexion Pharmaceuticals, where his responsibilities included developing and supporting all manufacturing processes globally as well as global clinical supply chain. Derek holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. in Chemical Engineering with High Distinction from Worcester Polytechnic Institute (WPI).

Jean Bender | Vice President, Pharmaceutical Sciences & Technology | Visterra, Inc.

Jean Bender

Vice President Pharmaceutical Sciences & Technology

Jean Bender leads Visterra’s Pharmaceutical Sciences department, responsible for development, technology transfer and manufacturing, clinical supply and CMC sections of regulatory submissions. Prior to Visterra, Jean was Senior Director, BioProcess Engineering at Medimmune. She has authored more than 15 publications and presentations and holds a patent for preparing highly concentrated antibodies by ultrafiltration. Jean received her MS in Chemical Engineering from the University of California, Berkeley and her BS in Chemical Engineering from Lehigh University. Jean has been on Pall’s Scientific Advisory Board and serves on the Recovery of Biological Products Board and on the Chemical Engineering Advisory Board for Lehigh University. Jean is active in the American Chemical Society and the BioInnovation Group (BIG).

David Fritsch | Head Engineer and PMO| BioInnovation Group

David Fritsch

Head of Engineering and Supply Chain and HSE
Landmark Bio

As Senior Director at Sanofi Genzyme, David is responsible to drive execution and delivery of Allston Site Strategy and the Cerezyme Manufacturing Project Portfolio. Responsibilities included the construction, installation and qualification of new process areas within the Allston Facility, while maintaining Cerezyme production to the market. Previously, David has acted as Senior Director, Engineering at Gallus Biopharmaceuticals (acquired by Patheon) where he was responsible for driving the development and growth of a multi-site, contract manufacturing organization (CMO) for the biopharmaceutical industry. David holds a B.S. Chemical Engineering from the University of Notre Dame and an MBA from Washington University in St. Louis. David is a Senior leader with extensive business and operations management experience in biologics, pharmaceuticals and chemicals manufacturing.

Neal Gordon | Independent Consultant| BioInnovation Group

Neal Gordon

Managing Director

Neal Gordon joined the BioProcess Technology Group of BDO in October 2019, as a Managing Director, following 30+ years in early-phase startups in the Boston-area life science industry. Neal is a hands-on leader with a strong record of technology innovation and translation of platform technologies into products. As an accomplished biotech executive and entrepreneur, he has been involved with a variety of companies pioneering novel, first-in-class therapeutic strategies and analysis platforms. These experiences provided valuable background not only in translation of scientific platforms into specific products but importantly in development of manufacturing, product characterization and lot release paradigms that accommodate existing regulation. Neal is a subject matter expert in process and analytical development with significant exposure to the emerging fields of cell and gene therapy.
Jorg Thommes | Head of CMC | Bill & Melinda Gates Medical Research Institute

Jorg Thommes

Executive Vice President Pharmaceutical Sciences & Operations
Repertoire Immune Medicines

Dr. rer. nat Jorg Thommes is the Executive Vice President of Pharmaceutical Sciences and Operations at Repertoire Immune Medicines with responsibility for developing Repertoire’s manufacturing, supply chain, and site infrastructure strategy. Prior to this he was Head of CMC at the Bill & Melinda Gates Medical Research Institute in Cambridge, MA, responsible for physical product development, manufacturing, and distribution across the entire portfolio. Previously, Dr. Thommes has acted as the Senior Vice President Pharmaceutical Sciences and Technology at Visterra and Senior Vice President, Engineering and Technology at Biogen, Inc., and his responsibilities included process development for all therapeutic modalities, global and site engineering, and manufacturing sciences. Dr. Thommes received a Diplom-Chemiker degree from University of Bonn, Germany, a Doctorate of Natural Sciences from University of Bonn, Germany, and a Habilitation Degree in Biochemical Engineering from University of Dusseldorf, Germany.

Executive Members

Susan Abu-Absi

Chief Technology & Manufacturing Officer
2seventy bio

Engin Ayturk

Executive Director, CMC Process Engineering & BioConjugation Development
Mersana Therapeutics

John Batal

Manager of Engineering
Nitto Denko Avecia

Huanchun Cui

Executive Director

Kathryn Golden

SVP Technical Operations & Cell Manufacturing

Dmitry Gumerov

Director Pharmaceutical Sciences & Technology

Stephen Hamilton

Chief Technical Officer
Wheeler Bio

Geoff Hodge

Chief Executive Officer
SOTIO Biotech US

Canping Jiang

Senior Director, Biologics Strategy and PMO
Thermo Fisher Scientific

Dr. Anne Kantardjieff

Vice President Manufacturing
BlueBird Bio

Michael Laska

Vice President, Process Development & Manufacturing
Sana Biotechnology

Carrie Mason

Associate Director Biologics R&D PAT/Automation

Michael Mietzner

Senior Vice President – New England
Agile GxP Advisors

Gregg Nyberg

Chief Technology Officer
Landmark Bio

Greg Papastoitsis

EVP of Process & Manufacturing Sciences
Ankyra Therapeutics

Todd Ranheim

Vaccine Technical Lead

Tom Ransohoff

Co-Head Biologics Franchise

Frank Riske

Managing Director, Bioprocess Technology Group

Joseph Shultz

Vice President Bioprocess and Product Development
Evelo Biosciences

Peter Wojciechowski

CMC Knowledge Management

Sarah Yuan

Chief Technical Operations Officer
Sigilon Therapeutics

Chun Zhang

Chief Technology & Quality Officer
Evelo Biosciences

Ask how BIG can showcase your technology at industry events and annual roundtables.

Follow Us on LinkedIn

Our Technology Showcase
Connect with us on LinkedIn